MCID: LCL004
MIFTS: 30

Localized Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Localized Osteosarcoma

MalaCards integrated aliases for Localized Osteosarcoma:

Name: Localized Osteosarcoma 12 15 73
Localized Osteogenic Sarcoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3356
NCIt 50 C7780
UMLS 73 C0278511

Summaries for Localized Osteosarcoma

MalaCards based summary : Localized Osteosarcoma, also known as localized osteogenic sarcoma, is related to blastic plasmacytoid dendritic cell and necrotizing sialometaplasia. An important gene associated with Localized Osteosarcoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways is Wnt Signaling Pathways: beta-Catenin-dependent Wnt Signaling. The drugs Cisplatin and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and monocytes, and related phenotype is skeleton.

Related Diseases for Localized Osteosarcoma

Diseases related to Localized Osteosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 blastic plasmacytoid dendritic cell 9.9 CDKN2A CLEC4C
2 necrotizing sialometaplasia 9.8 CDKN2A TIA1
3 b-cell lymphomas 9.7 CDKN2A TIA1
4 osteogenic sarcoma 9.7
5 body mass index quantitative trait locus 1 9.7
6 sarcoma 9.7

Graphical network of the top 20 diseases related to Localized Osteosarcoma:



Diseases related to Localized Osteosarcoma

Symptoms & Phenotypes for Localized Osteosarcoma

MGI Mouse Phenotypes related to Localized Osteosarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 skeleton MP:0005390 8.92 CDKN2A FRZB GLI2 TIA1

Drugs & Therapeutics for Localized Osteosarcoma

Drugs for Localized Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Not Applicable 23214-92-8 31703
4
leucovorin Approved Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
5
Methotrexate Approved Phase 3,Phase 2,Not Applicable 59-05-2, 1959-05-2 126941
6
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
7
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
8
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
10
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 6055-19-2, 50-18-0 2907
11
Peginterferon alfa-2b Approved Phase 3 99210-65-8, 215647-85-1
12
Zoledronic acid Approved Phase 3 118072-93-8 68740
13
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Not Applicable 59-30-3 6037
16
Doxil Approved June 1999 Phase 3,Phase 2,Not Applicable 31703
17 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
18 Anti-Bacterial Agents Phase 3,Phase 2,Not Applicable
19 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Anti-Infective Agents Phase 3,Phase 2,Not Applicable
22 Antiviral Agents Phase 3,Phase 2
23 interferons Phase 3,Phase 2
24 Interferon-alpha Phase 3,Phase 2
25 Adjuvants, Immunologic Phase 3,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
27 Antibiotics, Antitubercular Phase 3,Phase 2,Not Applicable
28 Protective Agents Phase 3,Phase 2,Not Applicable
29 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Not Applicable
30 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
32 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Vitamin B Complex Phase 3,Phase 2,Not Applicable
34 Dermatologic Agents Phase 3,Phase 2,Not Applicable
35 Folate Phase 3,Phase 2,Not Applicable
36 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Folic Acid Antagonists Phase 3,Phase 2,Not Applicable
38 Etoposide phosphate Phase 3,Phase 2,Phase 1
39 Antimitotic Agents Phase 3,Phase 2
40 razoxane Phase 3,Phase 2
41 Cardiotonic Agents Phase 3,Phase 2
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Antimetabolites, Antineoplastic Phase 3,Phase 2,Not Applicable
44 Vitamin B9 Phase 3,Phase 2,Not Applicable
45 Antimetabolites Phase 3,Phase 2,Not Applicable
46 sodium thiosulfate Phase 3
47 Liver Extracts Phase 3,Phase 1,Early Phase 1
48 Antioxidants Phase 3
49 Antitubercular Agents Phase 3
50 Chelating Agents Phase 3,Not Applicable

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
2 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
3 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
6 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
8 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
9 A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung Completed NCT00752206 Phase 2 Saracatinib;Placebo
10 Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma Completed NCT00245011 Phase 2 ifosfamide
11 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
12 Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery Terminated NCT00880542 Phase 2 sorafenib;Ifosfamide
13 Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma Terminated NCT00019864 Phase 2 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;leucovorin calcium;methotrexate
14 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
15 High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer Completed NCT00002854 Phase 1 carboplatin;cisplatin;cyclophosphamide;etoposide;ifosfamide;mesna;paclitaxel
16 Combination Chemotherapy in Treating Patients Undergoing Surgery for Newly Diagnosed High-Grade Osteosarcoma Completed NCT00645632 Not Applicable cisplatin;doxorubicin hydrochloride;ifosfamide;methotrexate
17 Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas Completed NCT01807052
18 Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma Completed NCT01062438
19 Study of Blood Samples From Patients With Osteosarcoma Completed NCT00954473
20 Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma Completed NCT01374672
21 Collecting and Storing Tissue From Young Patients With Cancer Completed NCT00898755
22 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
23 Electroacupuncture in Treating Delayed Nausea and Vomiting in Patients Receiving Chemotherapy For Newly Diagnosed Childhood Sarcoma, Neuroblastoma, Nasopharyngeal Cancer, Germ Cell Tumors, or Hodgkin Lymphoma Completed NCT00040911 Not Applicable
24 PET Scan Combined With CT Scan in Evaluating Treatment Response in Patients Undergoing Treatment for Bone Cancer or Soft Tissue Sarcoma Completed NCT00335751 Not Applicable
25 Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma Completed NCT00003793
26 DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma Active, not recruiting NCT01190943
27 Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study Not yet recruiting NCT03737435
28 Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer Terminated NCT00499733 Early Phase 1 cyclophosphamide
29 Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma Withdrawn NCT00334984 Not Applicable glutamine
30 Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection Withdrawn NCT00378781 Not Applicable Heparin;Minocycline-EDTA

Search NIH Clinical Center for Localized Osteosarcoma

Genetic Tests for Localized Osteosarcoma

Anatomical Context for Localized Osteosarcoma

MalaCards organs/tissues related to Localized Osteosarcoma:

41
Bone, Liver, Monocytes, B Cells

Publications for Localized Osteosarcoma

Articles related to Localized Osteosarcoma:

(show all 29)
# Title Authors Year
1
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. ( 30304898 )
2018
2
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1. ( 29340095 )
2017
3
P16 expression as a prognostic and predictive marker in high grade localized osteosarcoma of the extremities: An analysis of 357 cases. ( 27544803 )
2016
4
Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. ( 26381138 )
2015
5
Risk-Based Therapy for Localized Osteosarcoma. ( 26501936 )
2015
6
Characterization of localized osteosarcoma of the extremity in children, adolescents, and young adults from a single institution in South Texas. ( 24487915 )
2014
7
Prognostic value of pathologic fracture in patients with high grade localized osteosarcoma: A systemic review and meta-analysis of cohort studies. ( 25231396 )
2014
8
Reply to the Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. ( 25099264 )
2014
9
Letter to the editor: Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. ( 25106799 )
2014
10
Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma. ( 22972657 )
2013
11
Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: A children's oncology group study. ( 24178953 )
2013
12
Meta-analysis of limb salvage versus amputation for treating high-grade and localized osteosarcoma in patients with pathological fracture. ( 23226744 )
2012
13
Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group. ( 21480474 )
2011
14
Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial. ( 21656756 )
2011
15
Good prognosis of localized osteosarcoma in young patients treated with limb-salvage surgery and chemotherapy. ( 21563300 )
2011
16
Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. ( 21151406 )
2010
17
Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma. ( 20566424 )
2010
18
How can survival be improved in localized osteosarcoma? ( 20735316 )
2010
19
Risk stratification based on the clinical factors at diagnosis is closely related to the survival of localized osteosarcoma. ( 19021220 )
2009
20
Prognostic effect of pathologic fracture in localized osteosarcoma: a cohort/case controlled study at a single institute. ( 19294672 )
2009
21
Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. ( 18163171 )
2008
22
Initial tumor size predicts histologic response and survival in localized osteosarcoma patients. ( 18270971 )
2008
23
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. ( 16246977 )
2005
24
The feasibility of neoadjuvant high-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma: results of a phase II study. ( 15999369 )
2005
25
Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. ( 11596036 )
2001
26
Definitive intraoperative very high-dose radiotherapy for localized osteosarcoma in the extremities. ( 11516856 )
2001
27
Reproductive functions in female patients treated with adjuvant and neoadjuvant chemotherapy for localized osteosarcoma of the extremity. ( 11064353 )
2000
28
[Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients]. ( 10472560 )
1999
29
The treatment of localized osteosarcoma of the extremities: the Italian experience. Studies of the National Research Council. ( 1622856 )
1992

Variations for Localized Osteosarcoma

Expression for Localized Osteosarcoma

Search GEO for disease gene expression data for Localized Osteosarcoma.

Pathways for Localized Osteosarcoma

Pathways related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.8 FRZB GLI2

GO Terms for Localized Osteosarcoma

Biological processes related to Localized Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 skeletal system development GO:0001501 9.16 FRZB GLI2
2 negative regulation of cell growth GO:0030308 8.96 CDKN2A FRZB
3 cochlea morphogenesis GO:0090103 8.62 FRZB GLI2

Sources for Localized Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....